[{"indications": "Indications\u00a0severe inflammatory skin disorders\r\nsuch as eczemas unresponsive to less potent corticosteroids; psoriasis,\r\n\n(From 13.4 Topical corticosteroids: British National Formulary)\n13.4 Topical corticosteroids", "name": "BECLOMETASONE DIPROPIONATE - TOPICAL CORTICOSTEROIDS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nSide-effects\u00a0Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushing\u2019s syndrome (section 6.3.2), depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous areas; it is increased by occlusion. Local side-effects include:spread and worsening of untreated infection;thinning of the skin which may be restored over a period after stopping treatment but the original structure may never return;irreversible striae atrophicae and telangiectasia;contact dermatitis;perioral dermatitis;acne, or worsening of acne or rosacea;mild depigmentation which may be reversible;hypertrichosis also reported.In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/203251.htm", "doses": ["Apply thinly 1\u20132 times daily"]}, {"indications": "Indications\u00a0adjunct to aminosalicylates in acute\r\nmild to moderate ulcerative colitis; asthma (section 3.2); allergic and vasomotor rhinitis (section 12.2.1); oral ulceration [unlicensed\r\nindication] (section 12.3.1)", "name": "BECLOMETASONE DIPROPIONATE - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.2 Corticosteroids"], "cautions": "Cautions\u00a0section 6.3.2; interactions: Appendix 1 (corticosteroids)", "side-effects": "Side-effects\u00a0section 6.3.2; also nausea, constipation, headache,\r\nand drowsiness", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200263.htm", "doses": ["5\u00a0mg in the morning; max. duration of treatment 4 weeks; child safety and efficacy not established"], "pregnancy": "Pregnancy\u00a0section 6.3.2"}, {"indications": "Indications\u00a0prophylaxis of asthma (see also Management of Chronic Asthma\r\ntable)", "name": "BECLOMETASONE DIPROPIONATE - RESPIRATORY SYSTEM", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.2 Corticosteroids", "BECLOMETASONE DIPROPIONATE"], "cautions": "Cautions\u00a0\n(From 3.2 Corticosteroids: British National Formulary)\nCautions of inhaled corticosteroids\u00a0Inhaled corticosteroids should be used with caution in patients with systemic infection, see Infections (section 6.3.2).Paradoxical bronchospasm\u00a0The potential for paradoxical bronchospasm (calling for discontinuation and alternative therapy) should be borne in mind\u2014mild bronchospasm may be prevented by inhalation of a short-acting beta2 agonist beforehand (or by transfer from an aerosol inhalation to a dry powder inhalation).CFC-free inhalers\u00a0Chlorofluorocarbon (CFC) propellants in pressurised aerosol inhalers have been replaced by hydrofluoroalkane (HFA) propellants.Doses for corticosteroid CFC-free pressurised metered-dose inhalers may be different from traditional CFC-containing inhalers and may differ between brands, see MHRA/CHM advice below. For interactions: see Appendix 1 (corticosteroids)MHRA/CHM advice (July 2008)Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (Qvar\u00ae and Clenil Modulite\u00ae) are not interchangeable and should be prescribed by brand name; Qvar\u00ae has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as Clenil Modulite\u00ae;Fostair\u00ae is a combination beclometasone dipropionate and formoterol fumarate CFC-free pressurised metered-dose inhaler; Fostair\u00ae has extra-fine particles and is more potent than traditional beclometasone dipropionate CFC-free inhalers.", "side-effects": "Side-effects\u00a0\n(From 3.2 Corticosteroids: British National Formulary)\nSide-effects of inhaled corticosteroids\u00a0Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids (section 6.3.2), but adverse effects have been reported.High doses of inhaled corticosteroids (see Management of Chronic Asthma table) used for prolonged periods can induce adrenal suppression. Inhaled corticosteroids have been associated with adrenal crisis and coma in children; excessive doses should be avoided. Patients using high doses of inhaled corticosteroids should be given a \u2018steroid card\u2019 (section 6.3.2) and specific written advice to consider corticosteroid replacement during an episode of stress, such as severe intercurrent illness or an operation.High doses of inhaled corticosteroid have been associated with lower respiratory tract infections, including pneumonia, in older patients with chronic obstructive pulmonary disease.Bone mineral density may be reduced following long-term inhalation of higher doses of corticosteroids, predisposing patients to osteoporosis (section 6.6). It is therefore sensible to ensure that the dose of an inhaled corticosteroid is no higher than necessary to keep a patient\u2019s asthma under good control.In children, growth restriction associated with systemic corticosteroid therapy does not seem to occur with recommended doses of inhaled therapy; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. However, the height of children receiving prolonged treatment of inhaled corticosteroid should be monitored; if growth is slowed, referral to a paediatrician should be considered. Large-volume spacer devices should be used for administering inhaled corticosteroids in children under 15 years (see NICE guidance, section 3.1.5); they are also useful in older children and adults, particularly if high doses are required. Spacer devices increase airway deposition and reduce oropharyngeal deposition.A small risk of glaucoma with prolonged high doses of inhaled corticosteroids has been reported. Hoarseness, throat irritation, dysphonia, and candidiasis of the mouth or throat may occur with inhaled corticosteroids (see also below). Hypersensitivity reactions (including rash and angioedema) have been reported rarely. Paradoxical bronchospasm has been reported very rarely. Anxiety, depression, sleep disturbances, and behavioural changes including hyperactivity, irritability, and aggression (particularly in children), hyperglycaemia, cataracts, skin thinning and bruising have also been reported.Candidiasis\u00a0The risk of oral candidiasis can be reduced by using a spacer device with the corticosteroid inhaler; rinsing the mouth with water (or cleaning a child\u2019s teeth) after inhalation of a dose may also be helpful. Antifungal oral suspension or oral gel (section 12.3.2) can be used to treat oral candidiasis without discontinuing therapy.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/65569.htm", "doses": ["By aerosol inhalation, see Management of Chronic Asthma\r\ntable (important: for Clenil Modulite\u00ae and Qvar\u00ae, see under preparations)", "By inhalation of dry powder (important: for Asmabec\u00ae and Becodisks\u00ae, see\r\nunder preparations), 200\u2013400\u00a0micrograms twice daily; adjusted as necessary\r\nup to 800\u00a0micrograms twice daily; child over 5 years 100\u2013200\u00a0micrograms twice daily, adjusted as necessary"], "pregnancy": "Pregnancy\u00a0see section 3.1"}, {"indications": "Indications\u00a0prophylaxis of asthma (see also Management of Chronic Asthma\r\ntable)", "name": "BECLOMETASONE DIPROPIONATE Compound preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.2 Corticosteroids", "BECLOMETASONE DIPROPIONATE", "Compound preparations"], "cautions": "Cautions\u00a0\n(From 3.2 Corticosteroids: British National Formulary)\nCautions of inhaled corticosteroids\u00a0Inhaled corticosteroids should be used with caution in patients with systemic infection, see Infections (section 6.3.2).Paradoxical bronchospasm\u00a0The potential for paradoxical bronchospasm (calling for discontinuation and alternative therapy) should be borne in mind\u2014mild bronchospasm may be prevented by inhalation of a short-acting beta2 agonist beforehand (or by transfer from an aerosol inhalation to a dry powder inhalation).CFC-free inhalers\u00a0Chlorofluorocarbon (CFC) propellants in pressurised aerosol inhalers have been replaced by hydrofluoroalkane (HFA) propellants.Doses for corticosteroid CFC-free pressurised metered-dose inhalers may be different from traditional CFC-containing inhalers and may differ between brands, see MHRA/CHM advice below. For interactions: see Appendix 1 (corticosteroids)MHRA/CHM advice (July 2008)Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (Qvar\u00ae and Clenil Modulite\u00ae) are not interchangeable and should be prescribed by brand name; Qvar\u00ae has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as Clenil Modulite\u00ae;Fostair\u00ae is a combination beclometasone dipropionate and formoterol fumarate CFC-free pressurised metered-dose inhaler; Fostair\u00ae has extra-fine particles and is more potent than traditional beclometasone dipropionate CFC-free inhalers.", "side-effects": "Side-effects\u00a0\n(From 3.2 Corticosteroids: British National Formulary)\nSide-effects of inhaled corticosteroids\u00a0Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids (section 6.3.2), but adverse effects have been reported.High doses of inhaled corticosteroids (see Management of Chronic Asthma table) used for prolonged periods can induce adrenal suppression. Inhaled corticosteroids have been associated with adrenal crisis and coma in children; excessive doses should be avoided. Patients using high doses of inhaled corticosteroids should be given a \u2018steroid card\u2019 (section 6.3.2) and specific written advice to consider corticosteroid replacement during an episode of stress, such as severe intercurrent illness or an operation.High doses of inhaled corticosteroid have been associated with lower respiratory tract infections, including pneumonia, in older patients with chronic obstructive pulmonary disease.Bone mineral density may be reduced following long-term inhalation of higher doses of corticosteroids, predisposing patients to osteoporosis (section 6.6). It is therefore sensible to ensure that the dose of an inhaled corticosteroid is no higher than necessary to keep a patient\u2019s asthma under good control.In children, growth restriction associated with systemic corticosteroid therapy does not seem to occur with recommended doses of inhaled therapy; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. However, the height of children receiving prolonged treatment of inhaled corticosteroid should be monitored; if growth is slowed, referral to a paediatrician should be considered. Large-volume spacer devices should be used for administering inhaled corticosteroids in children under 15 years (see NICE guidance, section 3.1.5); they are also useful in older children and adults, particularly if high doses are required. Spacer devices increase airway deposition and reduce oropharyngeal deposition.A small risk of glaucoma with prolonged high doses of inhaled corticosteroids has been reported. Hoarseness, throat irritation, dysphonia, and candidiasis of the mouth or throat may occur with inhaled corticosteroids (see also below). Hypersensitivity reactions (including rash and angioedema) have been reported rarely. Paradoxical bronchospasm has been reported very rarely. Anxiety, depression, sleep disturbances, and behavioural changes including hyperactivity, irritability, and aggression (particularly in children), hyperglycaemia, cataracts, skin thinning and bruising have also been reported.Candidiasis\u00a0The risk of oral candidiasis can be reduced by using a spacer device with the corticosteroid inhaler; rinsing the mouth with water (or cleaning a child\u2019s teeth) after inhalation of a dose may also be helpful. Antifungal oral suspension or oral gel (section 12.3.2) can be used to treat oral candidiasis without discontinuing therapy.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200011.htm", "doses": ["By aerosol inhalation, see Management of Chronic Asthma\r\ntable (important: for Clenil Modulite\u00ae and Qvar\u00ae, see under preparations)", "By inhalation of dry powder (important: for Asmabec\u00ae and Becodisks\u00ae, see\r\nunder preparations), 200\u2013400\u00a0micrograms twice daily; adjusted as necessary\r\nup to 800\u00a0micrograms twice daily; child over 5 years 100\u2013200\u00a0micrograms twice daily, adjusted as necessary", "Name[Fostair\u00ae (Chiesi) ] Aerosol inhalation, beclometasone\r\ndipropionate 100\u00a0micrograms, formoterol fumarate 6\u00a0micrograms/metered\r\ninhalation, net price 120-dose unit = \u00a329.32. \r\n    Label:\r\n    8, counselling, administration, 10, steroid card with high dosesDose\u00a0by aerosol inhalation, asthma, adult over 18 years, 1\u20132 puffs twice daily; max.\r\n4 puffs dailyWhen switching patients from other beclometasone\r\ndipropionate and formoterol fumarate inhalers, Fostair\u00ae 100/6 can be prescribed for patients already using\r\nbeclometasone dipropionate 250\u00a0micrograms in another CFC-free inhaler;\r\nthe dose of Fostair\u00ae should be adjusted according\r\nto responseNote\u00a0The MHRA has advised (July 2008) that beclometasone\r\ndipropionate CFC-free inhalers should be prescribed by brand name"], "pregnancy": "Pregnancy\u00a0see section 3.1"}, {"indications": "Indications\u00a0adjunct to aminosalicylates in acute\r\nmild to moderate ulcerative colitis; asthma (section 3.2); allergic and vasomotor rhinitis (section 12.2.1); oral ulceration [unlicensed\r\nindication] (section 12.3.1)", "name": "BECLOMETASONE DIPROPIONATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.2 Corticosteroids"], "cautions": "Cautions\u00a0section 6.3.2; interactions: Appendix 1 (corticosteroids)", "side-effects": "Side-effects\u00a0section 6.3.2; also nausea, constipation, headache,\r\nand drowsiness", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200263.htm", "doses": ["5\u00a0mg in the morning; max. duration of treatment 4 weeks; child safety and efficacy not established"], "pregnancy": "Pregnancy\u00a0section 6.3.2"}, {"indications": "Indications\u00a0prophylaxis and\r\ntreatment of allergic and vasomotor rhinitis", "name": "BECLOMETASONE DIPROPIONATE - CORTICOSTEROIDS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.2 Drugs acting on the nose", "12.2.1 Drugs used in nasal allergy", "Corticosteroids", "BECLOMETASONE DIPROPIONATE"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, and also after nasal surgery (until healing has occurred); they should also be avoided in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids, see section 6.3.2. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local side-effects include dryness, irritation of nose and throat, and epistaxis. Nasal ulceration has been reported, but occurs commonly with nasal preparations containing fluticasone furoate or mometasone furoate. Nasal septal perforation (usually following nasal surgery) occurs very rarely. Raised intra-ocular pressure or glaucoma may occur rarely. Headache, smell and taste disturbances may also occur. Hyperactivity, sleep disturbances, anxiety, depression, and aggression have been reported particularly in children. Hypersensitivity reactions, including bronchospasm, have been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/60776.htm", "doses": ["adult and child over 6 years, 100\u00a0micrograms (2 sprays) into\r\neach nostril twice daily; max. total 400\u00a0micrograms (8 sprays) daily;\r\nwhen symptoms controlled, dose reduced to 50\u00a0micrograms (1 spray)\r\ninto each nostril twice daily"]}, {"indications": "Indications\u00a0prophylaxis and\r\ntreatment of allergic and vasomotor rhinitis", "name": "BECLOMETASONE DIPROPIONATE - DRUGS USED IN NASAL ALLERGY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.2 Drugs acting on the nose", "12.2.1 Drugs used in nasal allergy", "Corticosteroids", "BECLOMETASONE DIPROPIONATE"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, and also after nasal surgery (until healing has occurred); they should also be avoided in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids, see section 6.3.2. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local side-effects include dryness, irritation of nose and throat, and epistaxis. Nasal ulceration has been reported, but occurs commonly with nasal preparations containing fluticasone furoate or mometasone furoate. Nasal septal perforation (usually following nasal surgery) occurs very rarely. Raised intra-ocular pressure or glaucoma may occur rarely. Headache, smell and taste disturbances may also occur. Hyperactivity, sleep disturbances, anxiety, depression, and aggression have been reported particularly in children. Hypersensitivity reactions, including bronchospasm, have been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/60776.htm", "doses": ["adult and child over 6 years, 100\u00a0micrograms (2 sprays) into\r\neach nostril twice daily; max. total 400\u00a0micrograms (8 sprays) daily;\r\nwhen symptoms controlled, dose reduced to 50\u00a0micrograms (1 spray)\r\ninto each nostril twice daily"]}]